ReviewNature reviews. Urology2011
Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?
Review in Nature reviews. Urology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 2 syntheses or guidelines pooled it, 127 citations in OpenAlex.
- The role of telomerase reverse transcriptase (TERT) promoter mutations in prognosis in bladder cancer.Bioengineered · 2021Pooled it
- [Urine cytology - update 2013. A systematic review of recent literature].Der Urologe. Ausg. A · 2013Pooled it
- Review
- Integrative bulk and single-cell transcriptomic analysis reveals COL1A2-driven ECM remodeling and focal adhesion signaling associated with the transition from non-muscle-invasive to muscle-invasive bladder cancer.Frontiers in oncology · 2025Article
- Preclinical models of bladder cancer: BBN and beyond.Nature reviews. Urology · 2024Review
- Deciphering the molecular heterogeneity of intermediate- and (very-)high-risk non-muscle-invasive bladder cancer using multi-layeredFrontiers in oncology · 2024Article
- P53, CK20, and FGFR3 Overexpression is Associated with the Characteristics of Urothelial Cell Carcinoma of the BladderAsian Pacific journal of cancer prevention : APJCP · 2023Article
- Microtubule Dynamics Deregulation Induces Apoptosis in Human Urothelial Bladder Cancer Cells via a p53-Independent Pathway.Cancers · 2023Article
- Improvement of the Collection, Maintenance, and Analysis of Neoplastic Cells from Urine Specimens with the Use of CytoMatrix.Methods and protocols · 2021Article
- Promoter hypomethylation as potential confounder of Ras gene overexpression and their clinical significance in subsets of urothelial carcinoma of bladder.Molecular biology reports · 2021Article
- High Level of Aristolochic Acid Detected With a Unique Genomic Landscape Predicts Early UTUC Onset After Renal Transplantation in Taiwan.Frontiers in oncology · 2021Article
- MicroRNAs and target molecules in bladder cancer.Medical oncology (Northwood, London, England) · 2020Review
- The therapeutic and prognostic implications of molecular biomarkers in urothelial carcinoma.Translational cancer research · 2020Review
- Article
- Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review.Diagnostics (Basel, Switzerland) · 2020Review
- Prognostic Utility of FBLN2 Expression in Patients With Urothelial Carcinoma.Frontiers in oncology · 2020Article
- Cell Cycle Markers in the Evaluation of Bladder Cancer.Pathology oncology research : POR · 2020Article
- A Urine-Based Liquid Biopsy Method for Detection of Upper Tract Urinary Carcinoma.Frontiers in oncology · 2020Article
- Organ preservation in bladder cancer: an opportunity for truly personalized treatment.Nature reviews. Urology · 2019Review
- Biological significance of GATA3, cytokeratin 20, cytokeratin 5/6 and p53 expression in muscle-invasive bladder cancer.PloS one · 2019Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The unprecedented advances in cancer genetics and genomics are rapidly affecting the clinical management of solid tumors. Molecular diagnostics are now an integral part of routine clinical management for patients with lung, colon, and breast cancer. In sharp contrast, molecular biomarkers have been largely excluded from current management algorithms for urologic malignancies. The need for new treatment options that can improve upon the modest outcomes currently associated with muscle-invasive bladder cancer is evident, and validated prognostic molecular biomarkers that can help clinicians to identify patients in need of early, aggressive management are lacking. Robust predictive biomarkers that are able to forecast and stratify responses to emerging targeted therapies are also needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.